Efficacy of romosozumab followed by denosumab in glucocorticoid users; a randomized clinical trial
- 16 June 2026
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (9) , 2331-2342
Abstract
Summary The efficacy of romosozumab (ROMO) in treating glucocorticoid-induced osteoporosis remains unclear. This randomized clinical trial demonstrated that in patients initiating glucocorticoid therapy, a treatment regimen of 12 months of ROMO followed by 24 months of denosumab (DMAb) was effective compared to either 36 months of DMAb or bisphosphonate monotherapy. Purpose The efficacy of romosozumab (ROMO), an antibody against sclerostin—an inhibitor of Wnt signaling—in the treatment of glucocorticoid-induced osteoporosis remains uncertain, particularly regarding the sequential use of ROMO and denosumab (DMAb). This study aimed to compare the long-term efficacy of 12 months of ROMO followed by 24 months of DMAb (ROMO-DMAb) to 36 months of DMAb or bisphosphonates (BP) alone. Methods Patients with rheumatic diseases who had not previously received osteoporosis drugs and were newly treated with prednisolone ≥ 15 mg/day were randomly assigned to receive ROMO (ROMO-DMAb group), DMAb, or risedronate. Over a 36-month period, we measured bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip every 6 months. Results Thirty-nine patients (median [interquartile ranges] age 72.0 [67.3 – 78.8] years; 69.2% women; prednisolone dose 20.0 [15.0 – 50.0] mg/day) were enrolled. The median percent change in lumbar spine BMD from baseline at 36 months was greatest in the ROMO-DMAb group (ROMO-DMAb; 11.3 [6.8 – 13.8] %, DMAb; 9.4 [4.7 – 13.5] %, BP; 2.1 [-1.3 – 6.8] %). The changes in the femoral neck and total hip were similar between the ROMO-DMAb and DMAb groups, and the increases were much smaller than that in the lumbar spine. Serum levels of total type I procollagen-N-propeptide and tartrate-resistant acid phosphatase-5b decreased in all groups from month 3. Conclusion Sequential treatment with ROMO followed by DMAb increased lumbar spine BMD more than DMAb or BP alone up to 36 months, demonstrating the efficacy of this treatment strategy.Keywords
Funding Information
- JSPS KAKENHI (JP 21K16665)
- Project Research Grant from Toho University School of Medicine (No.19-19)
This publication has 33 references indexed in Scilit:
- Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in JapanOsteoporosis International, 2024
- Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy TrialArthritis & Rheumatology, 2019
- Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritisOsteoporosis International, 2016
- Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trialsOsteoporosis International, 2015
- Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitusOsteoporosis International, 2009
- Glucocorticoid-induced osteoporosis: pathophysiology and therapyOsteoporosis International, 2007
- Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimenJournal of Bone and Mineral Metabolism, 2006
- Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studiesJournal of Bone and Mineral Metabolism, 2004
- A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group)Osteoporosis International, 2003
- The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysisOsteoporosis International, 2002